Enhance your practice with CME and tools that focus on diseases and conditions impacting the female patient.
Ongoing Trials in Oral Targeted Strategies in Breast Cancer
Aditya Bardia, MD, MPH, FASCO
SERENA-6: Acting on ESR1 Mutations in Advanced Breast Cancer
Erica L. Mayer, MD, MPH
Rapid Data Pulses From ASCO 2026: Emerging Data on Oral Targeted Strategies in Breast Cancer
22nd Annual Women’s Health Annual Visit (WHAV)
December 04, 2026
New York, New York
Escalate With Intention: Stepwise, Target-Anchored Moves
Christyn Edmundson, MD
Gil I. Wolfe MD, FAAN
Turning Flares Into Function: Flag Uncontrolled Disease
Treat. Target. Transform: Applying Treat-to-Target Principles in the Management of Generalized Myasthenia Gravis (gMG)
Minimal By Design: Define MSE Endpoints
November 13, 2026 Pasadena, California
From Abstract to Action in Breast Cancer: Interpreting Recent Data on Oral SERDs and Endocrine Targeting Strategies
Shared Goals, Shared Gains: Align With Patient Preferences
Scorecards That Matter: Use MG-ADL, MG-MMT, QMG, QoL
The 2-Point Signal: Apply ≥2-Point Rule
Capturing the Impact of Endometriosis on Health-Related QoL: The Role of Patient Questionnaires
Lee P. Shulman, MD, FACMG, FACOG
Ayman Al-Hendy, MD, PhD, FRCSC, FACOG, CCRP
Early Diagnosis: Its Pivotal Role in Optimizing Outcomes in Patients With Endometriosis – Psychosocial and Physical Consequences
Linda Bradley, MD
Samantha Denäe
The Integral Role of GnRH Antagonists in the Management of Endometriosis
Sawsan As-Sanie, MD
James A. Simon, MD, CCD, NCMP, IF, FACOG
Target Locked in gMG: Why T2T Matters
FcRn: Same Class, Different Paths—Spot Agent Differentiators
The Alloimmune Disorders of Pregnancy
Karin J. Blakemore, MD
Emilie L. Vander Haar
Clinical Considerations for the Diagnosis of Endometriosis
Pre- and Postoperative Use of GnRH Antagonists
Changing the Paradigm in the Management of Endometriosis: Moving Away From “Surgery First” to “Pharmacologic Therapy First”
Strategies to Address Healthcare Disparities in Patients With Endometriosis
Melissa Simon, MD
Why Are the Fetus and Placenta Not Rejected by the Mother? New Insights Into Maternal Anti-Fetal Rejection
Roberto Romero, MD, DMedSci
The IgG Clock: Redose Using IgG Kinetics
When to Begin FcRn: Initiation Criteria, Key Evidence
Can We Talk? Optimizing Patient Buy-In to the Management of Endometriosis
Cut to the Chase: Why Not Treat Endometriosis With GnRH Antagonists First?
Parallels Between Kidney Transplantation and Maternal Anti-Fetal Rejection
Alexandra Benachi, MD, PhD
Julien Zuber, MD, PhD
Alloimmune Neutropenia of the Fetus and Newborn
Masja de Haas, MD, PhD
Introduction to Alloimmunization During Pregnancy
Unmasking Preeclampsia, the Great Masquerader
Mario R. Nacinovich, Jr., MSc
Kara Rood, MD
Loading...
We're glad to see you're enjoying Omnia Education… but how about a more personalized experience?
Press cancel to remain on Omnia Education. Press the link below or the continue button to keep going.